Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C.

News & Events


Romark Establishes Manufacturing Operations In Belgium

New API Manufacturing Operations to Support Expansion of the Company's Business

TAMPA, Fla. – August 27, 2013 – Romark Laboratories ("Romark") announced that it has established a new subsidiary, Lapicor NV ("Lapicor"), to manufacture active pharmaceutical ingredients (APIs) in support of its global pharmaceutical business. Simultaneously, Lapicor has acquired the assets of Landen PhamaChem NV, a manufacturer of active pharmaceutical ingredient (API) in Belgium.

"The Lapicor API manufacturing operation will provide an important base to support our company's growth," said Marc Ayers, President and Chief Executive Officer of Romark. "The acquisition of the facility in Landen has secured the API manufacturing capacity required to support our existing products as well as NT-300 and other new products in development. Importantly, we are also pleased to have assembled a very competent management team to oversee the operation, a team with specific history and experience with the Lapicor facility."

Lapicor will employ approximately 25 persons initially and is expected to employ 50 to 100 employees within the next two years. The manufacturing facility located in Landen, Belgium was previously used for contract manufacturing of a broad range of APIs. In Lapicor's hands, it will be dedicated to producing APIs exclusively for Romark.

About Romark Laboratories

Romark Laboratories, L.C. is a vertically integrated pharmaceutical company committed to the discovery, development and delivery of innovative small molecule drugs for treating infectious diseases and cancers. The company is headquartered in Tampa, Florida. It markets Alinia® (nitazoxanide) tablets, 500 mg and Alinia® (nitazoxanide) for Oral Suspension, 100 mg/5 mL in the United States and is developing a new class of broad-spectrum antiviral drugs called thiazolides. Its late-stage investigational new drug, NT-300 (nitazoxanide), is undergoing Phase 3 clinical development for treatment of influenza.